ClinicalTrials.gg
Active, not recruitingNCT06328738Updated Nov 19, 2025

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

A Phase 1 interventional study of ELVN-002 and Trastuzumab in HER2-positive Breast Cancer, HER2-positive Gastric Cancer and HER2 Positive Solid Tumors, sponsored by Enliven Therapeutics. Active, not recruiting at 31 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Enliven Therapeutics · Phase 1, Interventional, and Treatment

How we know · 18 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
275
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Colorectal Neoplasms with a site in Spain — 97 open to participants now, 150 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.

Planned enrollment
146th of 405
275 · median 167
Started
2024
with 30 others
Phase 1
79 of 463
19 open now
Primary completion
2027-01
later than 52 of 149 live
Registered
382nd of 463
by date

Among the 463 studies in Colorectal Neoplasms with a site in Spain, this one is the 146th largest by planned enrollment of the 405 interventional ones that give a count, is one of 31 that started in 2024, is one of 79 in phase 1, reaches primary completion later than 52 of the 149 other live ones, and was the 382nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

97 of the 463 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

92 more — sign in →

All 97 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Colorectal Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage HER2-positive colorectal cancer and breast cancer.

Read the detailed description

Parts 1 and 3 of this study are designed to evaluate preliminary safety, tolerability, and pharmacokinetics (PK) of ELVN-002 in combination with trastuzumab in participants with advanced stage HER2 positive solid tumors. In addition, Part 3 will evaluate the preliminary efficacy of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive solid tumors.

Part 2 of this study will evaluate the preliminary safety, tolerability, and PK of ELVN-002 in combination with trastuzumab and chemotherapy; capecitabine and oxaliplatin(CAPEOX) or 5-fluorouracil (5-FU), leucovorin (LCV) and oxaliplatin (mFOLFOX6) in participants with advanced stage HER2 positive colorectal cancer, or eribulin or capecitabine in participants with advanced-stage HER2-positive breast cancer, or paclitaxel in participants with advanced stage solid tumors.

In part 4, the preliminary safety, tolerability, PK, and efficacy of ELVN-002 in combination with trastuzumab and CAPEOX or mFOLFOX6 will be evaluated in participants with HER2-positive colorectal cancer.

03

Conditions studied

  • HER2-positive Breast Cancer
  • HER2-positive Gastric Cancer
  • HER2 Positive Solid Tumors
  • HER2 Amplification
  • Colorectal Cancer

Keywords

  • ELVN-002
  • HER2 positive Colorectal Cancer
  • HER2 overexpression
  • HER2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or histologically documented solid tumor.
  • Locally advanced or disease or unresectable disease.
  • -positive disease based on the following local testing:

    • Colorectal cancer: IHC3+, IHC2+/ISH+, NGS amplification by tissue (no RAS or BRAF mutation allowed)
    • Breast cancer: IHC3+ or IHC2+/ISH+ by tissue
    • Gastric cancer: IHC3+ or IHC2+/ISH+ by tissue
    • Other cancers: IHC3+, IHC2+/ISH+, NGS amplification by tissue or ctDNA
  • Prior therapies for Part 1 (Dose Escalation ELVN-002 + trastuzumab):

    • Colorectal cancer: treated with prior fluoropyrimidine, oxaliplatin, irinotecan-based regimens, anti-epidermal growth factor receptor (EGFR) treatment (if clinically indicated), anti-vascular endothelial growth factor (VEGF) treatment (if clinically indicated), and an anti-programmed death ligand 1 (PD-(L)-1) treatment (if the tumor is microsatellite instability (MSI)-high/deficient mismatch repair (dMMR)
    • Breast cancer: treated with prior taxane, pertuzumab, trastuzumab, and fam-trastuzumab deruxtecan (T-DXd) if available and appropriate based on local standard of care and investigator's assessment
    • Gastric cancer: treated with trastuzumab/platinum fluorouracil containing regimen and T-DXd.
    • Other cancers: progressed during or after ≥ 1 for locally advanced unresectable or metastatic disease
    • Prior HER2 targeted therapy is allowed
  • Prior therapies for Part 2 (Phase 1a Dose Escalation ELVN-002 + trastuzumab + chemotherapy):

    • Colorectal cancer: candidate for CAPEOX (capecitabine and oxaliplatin) or mFOLFOX6 (5-FU, LCV and oxaliplatin), and treated, if clinically indicated, with an anti-programmed death ligand 1 (PD-(L)-1) treatment (if the tumor is microsatellite instability (MSI)-high/deficient mismatch repair (dMMR). Prior HER2 targeted therapy is allowed.
    • Breast cancer: candidate for capecitabine, paclitaxel or eribulin, and treated with prior taxane, pertuzumab, trastuzumab, and T-DXd, if available and appropriate, based on local standard of care and investigator's assessment. No prior HER2 targeted tyrosine kinase inhibitor therapy (antibody-drug conjugates and antibodies are allowed), no prior capecitabine (for the capecitabine cohort), no prior eribulin (for the eribulin cohort), and no taxane as immediate prior therapy (paclitaxel cohort).
  • Prior therapies for Part 3 (Phase 1b Dose Expansion ELVN-002 + trastuzumab):

    • Colorectal cancer: treated with prior fluoropyrimidine, oxaliplatin, irinotecan-based regimens, anti-epidermal growth factor receptor (EGFR) treatment (if clinically indicated), anti-vascular endothelial growth factor (VEGF) treatment (if clinically indicated), and an anti-programmed death ligand 1 (PD-(L)-1) treatment if the tumor is microsatellite instability (MSI)-high/deficient mismatch repair (dMMR). No prior HER2 targeted therapy.
    • Breast cancer: treated with prior taxane, pertuzumab, trastuzumab, and T-DXd if available and appropriate based on local standard of care and investigator's assessment. No prior HER2 targeted tyrosine kinase inhibitor therapy (antibody-drug conjugates and antibodies are allowed).
    • Gastric cancer: treated with prior trastuzumab/platinum fluorouracil containing regimen and T-DXd. No prior HER2 targeted therapy.
    • Other cancers: Progressed during or after ≥ 1 prior line of systemic therapy for locally advanced unresectable or metastatic disease. No prior HER2 targeted therapy.
  • Prior therapies for Part 4 (Phase 1b Dose Expansion ELVN-002 + trastuzumab + chemotherapy):

    * Colorectal cancer: candidate for CAPEOX or mFOLFOX6 and not a candidate for first-line anti-programmed death ligand 1 (PD-(L)-1) treatment (if the tumor is microsatellite instability (MSI)-high/deficient mismatch repair (dMMR). No prior therapy for metastatic disease (1 cycle of mFOLFOX6 or 1 cycle of CAPEOX allowed). No prior HER2 targeted therapy.

  • At least 1 based on v 1.1 within 6 weeks before the first dose of ELVN-002 (Part 3 and Part 4 only; Phase 1b Dose Expansion cohorts)
  • (ECOG) performance status of 0-1
  • Adequate hematological, hepatic, renal, and cardiac function

Exclusion criteria

Exclusion Criteria:

  • Treatment with anticancer therapy within a specific time before the first dose:

    • Chemotherapy (including ADC) ≤ 3 weeks
    • Immunotherapy ≤ 4 weeks
    • Hormonal therapy ≤ 2 weeks
    • TKI ≤ 2 weeks
    • Any experimental therapy ≤ 3 weeks or 5 half-lives, whichever is longer
    • Radiotherapy-wide therapy ≤ 3 weeks
    • Radiotherapy limited field (including stereotactic brain) ≤ 2 weeks
    • Antibody ≤ 3 weeks
  • Any brain lesion requiring immediate local therapy
  • Ongoing use of for central nervous system (CNS) symptoms at a dose of > 2 mg daily of dexamethasone (or equivalent)
  • Uncontrolled seizures
  • Participants for any chemotherapy cohort: ongoing Grade 2 or higher neuropathy of any cause
  • Inability to swallow pills or any significant gastrointestinal disease that would preclude adequate oral absorption of medications.
  • Ongoing adverse effects from prior treatment > Grade 1 except for Grade 2 alopecia
  • interval (QTc) of >470 milliseconds (ms) for females or >450 ms for males
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
275 participants (estimated)

Study arms

  • Experimental
    Part 1: ELVN-002 + trastuzumab dose escalation

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.

    Drug: ELVN-002 · Drug: Trastuzumab

  • Experimental
    Part 2A: ELVN-002 + trastuzumab + CAPEOX dose escalation in colorectal cancer

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1000 mg/m2 on days 1 - 14 of a 21-day cycle. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1 of a 21-day cycle.

    Drug: ELVN-002 · Drug: Trastuzumab · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    Part 2B: ELVN-002 + trastuzumab + mFOLFOX6 dose escalation in colorectal cancer

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered intravenously at 6 mg/kg IV cycle 1, day 2 followed by 4 mg/kg IV cycle 1, day 15, and then one dose at 4mg/kg IV every 14 days. Fluorouracil (5-FU) will be administered intravenously as a 400 mg/m2 IV bolus on days 1 and 15 followed by 2400 mg/m2 over 46-48 hours of continuous infusion on days 1-3 and days 15-17 of a 28-day cycle. Leucovorin will be administered intravenously at 400 mg/m2 concurrently with oxaliplatin on days 1 and 15 of a 28-day cycle. Oxaliplatin will be administered intravenously at 85 mg/m2 IV on day 1 and 15 of a 28-day cycle.

    Drug: ELVN-002 · Drug: Trastuzumab · Drug: 5-Fluorouracil · Drug: Oxaliplatin · Drug: Leucovorin

  • Experimental
    Part 2C: ELVN-002 + trastuzumab + capecitabine dose escalation in breast cancer

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1000 mg/m2 on days 1 - 14 of a 21-day cycle.

    Drug: ELVN-002 · Drug: Trastuzumab · Drug: Capecitabine

  • Experimental
    Part 2D: ELVN-002 + trastuzumab + paclitaxel dose escalation in solid tumors

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Paclitaxel will be administered intravenously at 80 mg/m2 on days 1, 8, and 15 of a 21-day cycle.

    Drug: ELVN-002 · Drug: Trastuzumab · Drug: paclitaxel

  • Experimental
    Part 2E: ELVN-002 + trastuzumab + eribulin dose escalation in breast cancer

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Eribulin will be administered intravenously at 1.4 mg/m2 on days 1 and 8 of a 21-day cycle.

    Drug: ELVN-002 · Drug: Trastuzumab · Drug: Eribulin

  • Experimental
    Part 3A: ELVN-002 + trastuzumab dose expansion in colorectal cancer

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+

    Drug: ELVN-002 · Drug: Trastuzumab

  • Experimental
    Part 3B: ELVN-002 + trastuzumab dose expansion in breast cancer

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.

    Drug: ELVN-002 · Drug: Trastuzumab

  • Experimental
    Part 3C: ELVN-002 + trastuzumab dose expansion in other solid tumor type 1

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.

    Drug: ELVN-002 · Drug: Trastuzumab

  • Experimental
    Part 3D: ELVN-002 + trastuzumab dose expansion in other solid tumor type 2

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.

    Drug: ELVN-002 · Drug: Trastuzumab

  • Experimental
    Part 3E: ELVN-002 + trastuzumab dose expansion in other solid tumor type 3

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.

    Drug: ELVN-002 · Drug: Trastuzumab

  • Experimental
    Part 4A: ELVN-002 + trastuzumab + CAPEOX dose expansion in colorectal cancer

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1000 mg/m2 on Days 1 - 14 of a 21-day cycle. Oxaliplatin: will be administered intravenously at 130 mg/m2 on Day 1 of a 21-day cycle.

    Drug: ELVN-002 · Drug: Trastuzumab · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    Part 4B: ELVN-002 + trastuzumab + mFOLFOX6 dose expansion in colorectal cancer

    ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered intravenously at 6 mg/kg IV cycle 1, day 2 followed by 4 mg/kg IV cycle 1, day 15, and then one dose at 4mg/kg IV every 14 days. Fluorouracil (5-FU) will be administered intravenously as a 400 mg/m2 IV bolus on days 1 and 15 followed by 2400 mg/m2 over 46-48 hours of continuous infusion on days 1-3 and days 15-17 of a 28-day cycle. Leucovorin will be administered intravenously at 400 mg/m2 concurrently with oxaliplatin on days 1 and 15 of a 28-day cycle. Oxaliplatin will be administered intravenously at 85 mg/m2 IV on days 1 and 15 of a 28-day cycle.

    Drug: ELVN-002 · Drug: Trastuzumab · Drug: 5-Fluorouracil · Drug: Oxaliplatin · Drug: Leucovorin

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs; Phase 1a only)

    DLTs will be used to support that the recommended doses for expansion are \</= maximum tolerated dose (MTD)

    Time frame: 21 days

  2. Incidence of adverse events (AEs)

    AEs will be used to support that the recommended doses for expansion are likely to be tolerable

    Time frame: 24 months

  3. Incidence of laboratory abnormalities

    Clinically significant laboratory abnormalities will be used to support that the recommended doses for expansion are likely to be tolerable

    Time frame: 24 months

  4. Incidence of electrocardiogram abnormalities

    Clinically significant electrocardiogram abnormalities will be used to support that the recommended doses for expansion are likely to be tolerable

    Time frame: 24 months

Secondary outcomes

  1. PK parameter of area under the curve of ELVN-002 (Phase 1a only)

    The concentration of ELVN-002 measured in the blood over 24 hours at steady state

    Time frame: 24 months

  2. PK parameter of maximum concentration of ELVN-002 (Phase 1a only)

    The maximum concentration of ELVN-002 measured in the blood at any time point at steady state

    Time frame: 24 months

  3. PK parameter of minimum concentration of ELVN-002 (Phase 1a only)

    The minimum concentration of ELVN-002 measured in the blood at any time point at steady

    Time frame: 24 months

  4. PK parameter of terminal half life of ELVN-002 (Phase 1a only)

    The half life of ELVN-002 calculated from the concentration of ELVN-002 measured in blood

    Time frame: 24 months

  5. Confirmed objective response rate (ORR)

    For patients with measurable disease at baseline, confirmed response as assessed by investigator per RECIST v1.1

    Time frame: 24 months

  6. Duration of response (DOR; Phase 1b only)

    The time from the first response to progression or death per RECIST v1.1

    Time frame: 24 months

  7. Brain metastases response (Phase 1b only)

    For patients with measurable brain metastases at baseline, the percent of patients who have a confirmed response per RECIST v1.1

    Time frame: 24 months

07

Study locations

31 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 32 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2024
First posted
Mar 25, 2024
StartActual
May 30, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jul 2028
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06328738
Lead sponsor
Enliven Therapeutics
Responsible party
Sponsor
First posted
Mar 25, 2024
Start date
May 30, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion